IBDwatch

Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.

May 24, 2019 ibdwatch

Related Articles Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther. 2019 May 23;: Authors: Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande Casteele N, Khanna R, Panaccione R, Feagan BG, Jairath V Abstract BACKGROUND: Janus kinase (JAK) inhibitors represent a novel therapeutic class for treatment of inflammatory bowel disease. AIMS: To determine the efficacy and safety of JAK inhibitors compared to placebo for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). METHODS:…

Perianal abscesses in infants are not associated with Crohn’s disease in a surgical cohort.

May 24, 2019May 24, 2019 ibdwatch

Perianal abscesses in infants are not associated with Crohn’s disease in a surgical cohort. J Crohns Colitis. 2019 May 22;: Authors: Roskam M, de Meij T, Bakx R, Gemke R Abstract BACKGROUND AND AIMS: The aim of this study is to search for an association between infantile perianal abscesses and (development of) Crohn’s disease in a surgical population of children. METHODS: Patients who were surgically treated in the Amsterdam UMC between January 2000 and December 2014 were included in this retrospective cohort study. Data collected: sex, date of birth, underlying…

Long-term Outcomes of Paediatric Patients Admitted with Acute Severe Colitis – A Multicenter Study from the Paediatric IBD Porto Group of ESPGHAN.

May 24, 2019May 24, 2019 ibdwatch

Long-term Outcomes of Paediatric Patients Admitted with Acute Severe Colitis – A Multicenter Study from the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. 2019 May 23;: Authors: Krauthammer A, Tzivinikos C, Assa A, Miele E, Strisciuglio C, Urlep D, Serban ED, Singh A, Winter HS, Russell RK, Hojsak I, Malham M, Navas-López VM, Croft NM, Lee HM, Ledder O, Shamasneh I, Hussey S, Huynh H, Wine E, Shah N, Sladek M, de Meij TG, Romano C, Dipasquale V, Lionetti P, Afzal NA, Aloi M, Lee K, Martín-de-Carpi J,…

Herbs-partitioned moxibustion alleviates aberrant intestinal epithelial cell apoptosis by upregulating A20 expression in a mouse model of Crohn’s disease.

May 23, 2019 ibdwatch

Related Articles Herbs-partitioned moxibustion alleviates aberrant intestinal epithelial cell apoptosis by upregulating A20 expression in a mouse model of Crohn’s disease. World J Gastroenterol. 2019 May 07;25(17):2071-2085 Authors: Zhou J, Wu LY, Chen L, Guo YJ, Sun Y, Li T, Zhao JM, Bao CH, Wu HG, Shi Y Abstract BACKGROUND: A20 inhibits intestinal epithelial cell apoptosis in Crohn’s disease, and herbs-partitioned moxibustion (HPM) has been demonstrated to be an effective treatment for Crohn’s disease. However, the mechanism by which HPM reduces intestinal epithelial cell apoptosis in Crohn’s disease has not…

Transitions of care across hospital settings in patients with inflammatory bowel disease.

May 23, 2019 ibdwatch

Related Articles Transitions of care across hospital settings in patients with inflammatory bowel disease. World J Gastroenterol. 2019 May 07;25(17):2122-2132 Authors: Warren LR, Clarke JM, Arora S, Barahona M, Arebi N, Darzi A Abstract BACKGROUND: Inflammatory bowel disease (IBD) is a chronic, inflammatory disorder characterised by both intestinal and extra-intestinal pathology. Patients may receive both emergency and elective care from several providers, often in different hospital settings. Poorly managed transitions of care between providers can lead to inefficiencies in care and patient safety issues. To ensure that the sharing of…

Proposal to Update the Curriculum in Inflammatory Bowel Diseases for Categorical Gastroenterology Fellows.

May 23, 2019May 23, 2019 ibdwatch

Proposal to Update the Curriculum in Inflammatory Bowel Diseases for Categorical Gastroenterology Fellows. Inflamm Bowel Dis. 2019 May 22;: Authors: Malter LB, Israel A, Rubin DT Abstract Education in inflammatory bowel disease (IBD) varies widely between categorical gastroenterology (GI) programs and is largely related to the presence of expert clinicians, patient population, and the presence of an IBD center. The treatment of IBD is becoming increasingly complex at a rapid pace, widening this educational divide. This manuscript outlines all the current US educational offerings in IBD for GI fellows, including…

CARMIL2 Deficiency Presenting as Very Early Onset Inflammatory Bowel Disease.

May 23, 2019May 23, 2019 ibdwatch

CARMIL2 Deficiency Presenting as Very Early Onset Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 May 22;: Authors: Magg T, Shcherbina A, Arslan D, Desai MM, Wall S, Mitsialis V, Conca R, Unal E, Karacabey N, Mukhina A, Rodina Y, Taur PD, Illig D, Marquardt B, Hollizeck S, Jeske T, Gothe F, Schober T, Rohlfs M, Koletzko S, Lurz E, Muise AM, Snapper SB, Hauck F, Klein C, Kotlarz D Abstract BACKGROUND: Children with very early onset inflammatory bowel diseases (VEO-IBD) often have a refractory and severe disease course. A significant…

Circadian Rhythm Disruption Aggravates DSS-Induced Colitis in Mice with Fecal Calprotectin as a Marker of Colitis Severity.

May 23, 2019 ibdwatch

Circadian Rhythm Disruption Aggravates DSS-Induced Colitis in Mice with Fecal Calprotectin as a Marker of Colitis Severity. Dig Dis Sci. 2019 May 21;: Authors: Amara J, Saliba Y, Hajal J, Smayra V, Bakhos JJ, Sayegh R, Fares N Abstract BACKGROUND: Inflammatory bowel disease (IBD) is a chronic immunologically mediated pathology that remains a major health burden. Circadian rhythm disruption leads to a deregulation in the immune system which is a major risk factor for IBD. AIMS: Since fecal calprotectin (FC) has been a useful tool for monitoring IBD, we aimed…

The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis in real-life.

May 23, 2019 ibdwatch

The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis in real-life. Aliment Pharmacol Ther. 2019 May 22;: Authors: Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A Abstract BACKGROUND: CT-P13, a biosimilar of the reference product infliximab, has been approved for the treatment of ulcerative colitis on the basis of the results of trials conducted in patients with spondyloarthritis and rheumatoid arthritis. AIM: To compare the effectiveness and safety of CT-P13 and the reference product in infliximab-naive patients with ulcerative…

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn’s Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature.

May 23, 2019May 23, 2019 ibdwatch

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn’s Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. J Crohns Colitis. 2019 May 22;: Authors: Smeets FGM, Liedorp PR, van der Poel M, Miclea RL, Masclee AAM, Pierik M Abstract Use of ustekinumab in Crohn’s disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn’s disease, who developed an anaplastic large cell T cell…